Kavitha Ramaswamy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kavitha Ramaswamy has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Audrey Mauguen
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
3 shared publications Christopher Jon Forlenza
Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 shared publications- Kevin J. Curran
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
2 shared publications Maria Luisa Sulis
Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 shared publicationsNancy A. Kernan
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
2 shared publicationsNeerav N. Shukla
Memorial Sloan Kettering Cancer Center, Department of Pediatrics, New York, New York, United States
2 shared publications
Latest Publications
- 10 September 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (11) , e70686
The Impact of v‐SYMPHONY's Virtual Boot Camp on Trainee Transition From Residency to Fellowship
Background: Starting a pediatric subspecialty fellowship presents numerous challenges to trainees. Virtual Symposium of Pediatric Hematology/Oncology of New York (v‐SYMPHONY), an educational collaborative organized by 18 pediatric hematology–oncology (PHO) programs, initiated an annual bootcamp in 2022 aimed at easing the transition from pediatric residency to PHO fellowship. Methods: The bootcamp consisted of virtual clinical lectures and fellow‐led panels, which were created with input from diverse program leadership, educators, and past fellows using Kern's six‐step module of curriculum development. It was offered to incoming fellows, first in the NY/NJ/CT region, and subsequently expanded nationally. Results: Over 4 years (2022–2025), 147 pediatric residents completed this virtual bootcamp. The number of residents attending the live sessions increased from 19 in 2022 to 62 in 2025. Forty‐four participants completed pre‐ and post‐bootcamp surveys over this period, which showed significant improvement in both self‐reported medical knowledge and preparedness and reported a decrease in transition to fellowship anxiety scores. Conclusion: These results highlight the need and benefits of a standardized orientation program that can be delivered virtually to ease the transition of PHO trainees from residency to fellowship. Such a standardized curriculum is feasible, adaptable, and potentially scalable to a national level.
- 10 September 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (11) , e70686
The Impact of v‐SYMPHONY's Virtual Boot Camp on Trainee Transition From Residency to Fellowship
Background: Starting a pediatric subspecialty fellowship presents numerous challenges to trainees. Virtual Symposium of Pediatric Hematology/Oncology of New York (v‐SYMPHONY), an educational collaborative organized by 18 pediatric hematology–oncology (PHO) programs, initiated an annual bootcamp in 2022 aimed at easing the transition from pediatric residency to PHO fellowship. Methods: The bootcamp consisted of virtual clinical lectures and fellow‐led panels, which were created with input from diverse program leadership, educators, and past fellows using Kern's six‐step module of curriculum development. It was offered to incoming fellows, first in the NY/NJ/CT region, and subsequently expanded nationally. Results: Over 4 years (2022–2025), 147 pediatric residents completed this virtual bootcamp. The number of residents attending the live sessions increased from 19 in 2022 to 62 in 2025. Forty‐four participants completed pre‐ and post‐bootcamp surveys over this period, which showed significant improvement in both self‐reported medical knowledge and preparedness and reported a decrease in transition to fellowship anxiety scores. Conclusion: These results highlight the need and benefits of a standardized orientation program that can be delivered virtually to ease the transition of PHO trainees from residency to fellowship. Such a standardized curriculum is feasible, adaptable, and potentially scalable to a national level.
- Open Access
- 18 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (17) , 5899-5908
Outcomes of Adolescents and Young Adults with AML Treated on Pediatric vs Adult Protocols
Adolescents and young adults (AYA) with acute myeloid leukemia (AML) represent a biologically and clinically distinct population managed across pediatric and adult oncology services, with no established optimal treatment paradigm. In this single-center retrospective study, we analyzed 81 AYA patients aged 14-29 years with newly diagnosed AML treated at Memorial Sloan Kettering Cancer Center between 2010 and 2025. Patients were stratified by treating service, European LeukemiaNet (ELN) 2022 risk category, and induction regimen. Pediatric patients received two cycles of cytarabine, daunorubicin, and etoposide (ADE)-based induction, while adult patients received one cycle of cytarabine plus daunorubicin (7+3) induction-three of whom required 7+3 reinduction-followed by risk-adapted consolidation including allogeneic hematopoietic stem cell transplantation. Composite complete response rates were similar between adult and pediatric cohorts (79% vs. 78%), as were rates of MRD negativity by multicolor flow cytometry among responders (63% vs. 55%). Despite comparable depth of response, five-year overall survival favored adult-service patients in both the full cohort (77.9% vs. 56.7%) and the ELN 2022 intermediate-adverse risk subgroup (62.7% vs. 47.9%), while relapse-free survival was nearly identical. On multivariable analysis, ELN 2022 risk retained independent prognostic significance, whereas treatment protocol did not. These findings demonstrate that pediatric-style and adult AML regimens achieve comparable remission depth in AYA patients. The survival advantage observed with adult protocols challenges the assumption that further cytotoxic intensification improves outcomes in this population.
- 18 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (17) , 5899-5908
Open AccessOutcomes of Adolescents and Young Adults with AML Treated on Pediatric vs Adult Protocols
Adolescents and young adults (AYA) with acute myeloid leukemia (AML) represent a biologically and clinically distinct population managed across pediatric and adult oncology services, with no established optimal treatment paradigm. In this single-center retrospective study, we analyzed 81 AYA patients aged 14-29 years with newly diagnosed AML treated at Memorial Sloan Kettering Cancer Center between 2010 and 2025. Patients were stratified by treating service, European LeukemiaNet (ELN) 2022 risk category, and induction regimen. Pediatric patients received two cycles of cytarabine, daunorubicin, and etoposide (ADE)-based induction, while adult patients received one cycle of cytarabine plus daunorubicin (7+3) induction-three of whom required 7+3 reinduction-followed by risk-adapted consolidation including allogeneic hematopoietic stem cell transplantation. Composite complete response rates were similar between adult and pediatric cohorts (79% vs. 78%), as were rates of MRD negativity by multicolor flow cytometry among responders (63% vs. 55%). Despite comparable depth of response, five-year overall survival favored adult-service patients in both the full cohort (77.9% vs. 56.7%) and the ELN 2022 intermediate-adverse risk subgroup (62.7% vs. 47.9%), while relapse-free survival was nearly identical. On multivariable analysis, ELN 2022 risk retained independent prognostic significance, whereas treatment protocol did not. These findings demonstrate that pediatric-style and adult AML regimens achieve comparable remission depth in AYA patients. The survival advantage observed with adult protocols challenges the assumption that further cytotoxic intensification improves outcomes in this population.
- Open Access
- 25 April 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (8) , 2688-2694
Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML
Effective reinduction regimens are needed for children with relapsed and refractory acute myeloid leukemia (AML), as outcomes remain poor. Therapeutic options are limited in this heavily pretreated patient population, many of whom have reached lifetime recommended doses of anthracycline chemotherapy. The development of effective non-anthracycline–based salvage regimens is crucial to these patients who are at significant risk of life-threatening cardiotoxicity. We previously reported results of a phase 2 trial of a clofarabine-based regimen with topotecan, vinorelbine, and thiotepa (TVTC) in patients with relapsed acute leukemias. Here we report on an expanded bicenter cohort of 33 patients, <25 years of age, with relapsed/refractory AML treated with up to 2 cycles of the TVTC reinduction regimen from 2007 to 2018. The overall response rate, defined as complete remission or complete remission with partial recovery of platelet count, was 71.4% (95% confidence interval [CI], 41.9-91.6) for those patients in first relapse (n = 14) and 47.4% (95% CI, 24.4-71.1) for patients in second or greater relapse or with refractory disease. Responses were seen across multiple high-risk cytogenetic and molecular subtypes, with 84% of responders successfully bridged to allogeneic stem cell transplantation. The 5-year overall survival for patients in first relapse was 46.2% (95% CI, 19.1-73.3) and 50.0% (95% CI, 26.9-73.1) for patients who responded to TVTC. For pediatric and young adult patients with relapsed/refractory AML, TVTC reinduction compares favorably with currently used salvage regimens and warrants further exploration.
- 25 April 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (8) , 2688-2694
Open AccessClofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML
Effective reinduction regimens are needed for children with relapsed and refractory acute myeloid leukemia (AML), as outcomes remain poor. Therapeutic options are limited in this heavily pretreated patient population, many of whom have reached lifetime recommended doses of anthracycline chemotherapy. The development of effective non-anthracycline–based salvage regimens is crucial to these patients who are at significant risk of life-threatening cardiotoxicity. We previously reported results of a phase 2 trial of a clofarabine-based regimen with topotecan, vinorelbine, and thiotepa (TVTC) in patients with relapsed acute leukemias. Here we report on an expanded bicenter cohort of 33 patients, <25 years of age, with relapsed/refractory AML treated with up to 2 cycles of the TVTC reinduction regimen from 2007 to 2018. The overall response rate, defined as complete remission or complete remission with partial recovery of platelet count, was 71.4% (95% confidence interval [CI], 41.9-91.6) for those patients in first relapse (n = 14) and 47.4% (95% CI, 24.4-71.1) for patients in second or greater relapse or with refractory disease. Responses were seen across multiple high-risk cytogenetic and molecular subtypes, with 84% of responders successfully bridged to allogeneic stem cell transplantation. The 5-year overall survival for patients in first relapse was 46.2% (95% CI, 19.1-73.3) and 50.0% (95% CI, 26.9-73.1) for patients who responded to TVTC. For pediatric and young adult patients with relapsed/refractory AML, TVTC reinduction compares favorably with currently used salvage regimens and warrants further exploration.
- Open Access
- 28 November 2021
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (2) , 72.e1-72.e8
Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
- 28 November 2021
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (2) , 72.e1-72.e8
Open AccessImpact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
- Open Access
- 1 March 2021
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 27 (3) , S214-S215
Bridging Chemotherapy Prior to CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
- 1 March 2021
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 27 (3) , S214-S215
Open AccessBridging Chemotherapy Prior to CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia